| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$5,777 |
Notification regarding unquoted securities - WHC
|
31 Aug 2026 4:08PM |
$8.600 |
$7.040 |
fallen by
18.14%
|
|
| Lefroy Exploration Limited (LEX) ORDINARY FULLY PAID |
Materials |
$24 |
Change of Director's Interest Notice x 4
|
31 Aug 2026 4:08PM |
$0.165 |
$0.085 |
fallen by
48.48%
|
|
| MCS Services Limited (MSG) ORDINARY FULLY PAID |
Industrials |
$1 |
Settlement of claim - former security business
|
31 Aug 2026 4:07PM |
$0.004 |
$0.004 |
fallen by
0%
|
|
| Spenda Limited (SPX) ORDINARY FULLY PAID |
Information Technology |
$2 |
Appendix 4G & Corporate Governance Statement
|
31 Aug 2026 4:07PM |
$0.002 |
$0.002 |
fallen by
0%
|
|
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$18 |
Appendix 4G and Corporate Governance Statement
|
31 Aug 2026 4:06PM |
$0.010 |
$0.009 |
fallen by
10%
|
|
| Rectifier Technologies Ltd (RFT) ORDINARY FULLY PAID |
Industrials |
$6 |
Appendix 4E and Preliminary Final Report
|
31 Aug 2026 4:03PM |
$0.008 |
$0.004 |
fallen by
50%
|
|
RFT - Price-sensitive ASX Announcement
Full Release
Key Points
- Appendix 4E Preliminary Final Report for Rectifier Technologies Ltd for the year ended 30 June 2026.
- Revenue from ordinary activities fell 44.3% to $8,160,569.
- Loss after tax attributable to owners increased to $5,138,843 from $783,792 in the prior year.
- The result included an approximately $5.6 million provision for slow-moving and obsolete inventory.
- Net tangible assets per ordinary security declined to 0.68 cents from 1.13 cents.
- Cash and cash equivalents at 30 June 2026 were $1,984,851, down from $2,651,127.
- Net cash used in operating activities improved to $66,270 compared with $4,381,547 in the prior year.
- Inventories were $7,320,890 net of an obsolescence provision of $6,329,576.
- No dividends were paid, recommended or declared for the current or previous financial year.
- The company implemented cost-management, working-capital and inventory control measures while reviewing product and market opportunities.
- The financial statements were in the process of being audited and an unmodified opinion was expected.
- The report was signed by director Zong Xu Wang in Melbourne on 31 August 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$18 |
Appendix 4E and 2026 Annual Report
|
31 Aug 2026 4:02PM |
$0.010 |
$0.009 |
fallen by
10%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- Appendix 4E and Annual Report cover the full year ended 30 June 2026, with announcement date 31 August 2026.
- Algorae Pharmaceuticals Limited is referred to as 1AI, Algorae and the Company.
- The company operates a dual-track model of AI-enabled drug discovery and pharmaceutical commercialisation.
- AlgoraeOS is the company’s proprietary AI drug-combination prediction platform developed with the UNSW AI Institute and support from CSIRO Data61.
- The therapeutic pipeline includes AI-116 for dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.
- Commercial operations are conducted through wholly owned subsidiary AlgoraeRx Pty Ltd.
- During FY2026 Algorae executed five commercial agreements with Sakar Healthcare, Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Zydus Lifesciences and Torrent Pharmaceuticals.
- The company lodged its first product registration dossier with the TGA, which was accepted for evaluation on 2 April 2026.
- No product revenue was recognised during the year.
- Total revenue and other income was $77,667, down from $141,050 in FY2025.
- Loss before income tax was $3,095,190, compared with $1,540,136 in FY2025.
- Net loss after tax attributable to members was $2,710,723, compared with $802,958 in FY2025.
- The increase in losses was attributed mainly to higher operating expenses, higher share-based payments and a lower R&D tax refund, including costs from commercial pharmaceutical operations.
- There were no dividends paid, recommended or declared for FY2026 or FY2025.
- Net tangible assets per ordinary share were 0.24 cents at 30 June 2026, up from 0.13 cents a year earlier.
- Net assets increased to $4,261,334 from $2,228,796.
- Cash at bank increased to $3,187,323 and term deposits were $750,000 at year end.
- Operating cash outflow was $2,603,932 for the year.
- The company had an undrawn $3.0 million receivables-based working capital facility with ScotPac at 30 June 2026.
- Inventories of $180,744 were recognised at year end, reflecting the new commercial operations.
- A new controlled entity, Algorae Sciences Pty Ltd, was added during the year.
- Algorae launched AlgoraeOS version 2 in November 2025, with expanded training data, multi-metric synergy prediction and uncertainty-weighted outputs.
- The company reported independent preclinical validation work at Peter MacCallum Cancer Centre supporting AlgoraeOS predictions.
- AOS2 generated more than 500,000 potential CBD-drug-cell line combinations in the first single-anchor program and more than 9 million predictions in a later multi-anchor program.
- The company became a foundation participant and healthcare and life sciences launch partner in the Sovereign AI Infrastructure initiative in June 2026.
- On 1 July 2026, after year end, the company announced it had been awarded a NSW Health public hospital supply contract.
- The next Annual General Meeting is scheduled for 5 November 2026.
- The financial statements were audited and an unmodified audit opinion was issued by PKF Perth.
- The annual report states the group complies with Australian Accounting Standards and IFRS.
- FY2027 priorities include progressing TGA submissions, commencing supply under commercial agreements, completing the second independent validation program and finalising shortlisted AOS2 candidates.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$28 |
Change of Director's Interest Notice
|
31 Aug 2026 4:01PM |
$0.021 |
$0.010 |
fallen by
52.38%
|
|
| Rectifier Technologies Ltd (RFT) ORDINARY FULLY PAID |
Industrials |
$6 |
Provision for Inventory
|
31 Aug 2026 4:00PM |
$0.008 |
$0.004 |
fallen by
50%
|
|
RFT - Price-sensitive ASX Announcement
Full Release
Key Points
- RFT will recognise a non-cash inventory provision of $5.6 million for the year ended 30 June 2026.
- The majority of the inventory was linked to an order from an Australian charging company that subsequently entered administration.
- RFT has been reselling some inventory, but the process is expected to take an extended period because of the large stock volume.
- Certain inventory items require modification or customisation to suit different customers.
- The Board cited uncertainty in the prevailing economic environment as a factor in making the provision.
- RFT said it will continue to actively market the inventory and seek to maximise its realisable value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metrics Real Estate Multi-Strategy Fund (MRE) FULLY PAID UNITS STAPLED SECURITIES |
- |
$220 |
Appendix 4E Preliminary Final Report
|
31 Aug 2026 4:00PM |
$1.730 |
$1.450 |
fallen by
16.18%
|
|
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$28 |
Notification of cessation of securities - BOT
|
31 Aug 2026 3:58PM |
$0.020 |
$0.010 |
fallen by
50%
|
|
| Elixinol Wellness Limited (EXL) ORDINARY FULLY PAID |
Consumer Staple |
$3 |
EXL Appendix 4D and Half-year Financial Report
|
31 Aug 2026 3:56PM |
$0.007 |
$0.006 |
fallen by
14.29%
|
|
EXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Half-year report covers the period ended 30 June 2026 for Elixinol Wellness Limited.
- Revenue from ordinary activities increased 2.2% to $7.813 million.
- Revenue from continuing operations increased 5.8% to $7.197 million.
- Loss after tax attributable to shareholders improved to $1.071 million from $3.093 million in the prior corresponding period.
- Basic and diluted loss per share were 0.26 cents.
- No dividends were paid, recommended or declared.
- Net tangible assets per ordinary security were negative 0.54 cents.
- Gross margin improved to 43% from 33%.
- Operating expenses fell 25% to $3.325 million.
- Adjusted EBITDA loss improved to $134,000 from $2.094 million.
- The Healthy Chef revenue grew 22% and Hemp Foods Australia grew 14%.
- The US business was classified as a discontinued operation and held for sale.
- Discontinued US operations recorded a $98,000 loss for the half.
- Cash and cash equivalents at 30 June 2026 were $996,000.
- Net operating cash outflow improved to $712,000 from $1.383 million.
- Net assets were $6.364 million at 30 June 2026.
- Borrowings totalled $3.753 million.
- Intangible assets were $4.845 million after a $123,000 impairment tied to Ananda Brands.
- Current liabilities exceeded current assets by $1.547 million, creating a material uncertainty related to going concern.
- After period end, the company received an offer to divest US business assets and had convertible note subscriptions of $1.055 million.
- The auditor issued an unmodified review conclusion but included a material uncertainty related to going concern emphasis.
- The report was signed and authorised for release on 31 August 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Camplify Holdings Limited (CHL) ORDINARY FULLY PAID |
Industrials |
$29 |
Change of Director's Interest Notice
|
31 Aug 2026 3:53PM |
$0.360 |
$0.350 |
fallen by
2.78%
|
|
| JB Hi-Fi Limited (JBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$8,464 |
Change of Director's Interest Notice - N Wells
|
31 Aug 2026 3:53PM |
$67.445 |
$77.410 |
risen by
14.78%
|
|
| Metrics Master Income Trust (MXT) ORDINARY UNITS FULLY PAID |
Financials |
$2,018 |
Appendix 4E Preliminary Final Report
|
31 Aug 2026 3:50PM |
$1.883 |
$1.645 |
fallen by
12.62%
|
|
| Thorney Technologies Ltd (TEK) ORDINARY FULLY PAID |
Financials |
$32 |
Notification of cessation of securities - TEK
|
31 Aug 2026 3:50PM |
$0.105 |
$0.092 |
fallen by
12.38%
|
|
| Steamships Trading Company Limited (SST) 50 TOEA ORDINARY FULLY PAID |
Industrials |
$279 |
Dividend/Distribution - SST
|
31 Aug 2026 3:50PM |
$9.550 |
$9.000 |
fallen by
5.76%
|
|
| Elixinol Wellness Limited (EXL) ORDINARY FULLY PAID |
Consumer Staple |
$3 |
Notification regarding unquoted securities - EXL
|
31 Aug 2026 3:49PM |
$0.007 |
$0.006 |
fallen by
14.29%
|
|
| King River Resources Limited (KRR) ORDINARY FULLY PAID |
Materials |
$69 |
Section 708(A) Cleansing Notice
|
31 Aug 2026 3:49PM |
$0.078 |
$0.043 |
fallen by
44.87%
|
|
| Janus Henderson Global Sustainable (Managed Fund) (FUTR) |
Financials |
$2 |
Monthly Factsheet - July 2026
|
31 Aug 2026 3:49PM |
$36.550 |
$35.920 |
fallen by
1.72%
|
|
| Metrics Income Opportunities Trust (MOT) ORDINARY UNITS FULLY PAID |
Financials |
$438 |
Appendix 4E Preliminary Final Report
|
31 Aug 2026 3:48PM |
$1.605 |
$1.310 |
fallen by
18.38%
|
|
| Janus Henderson Sustainable Credit Active ETF (Managed Fund) (GOOD) |
Financials |
$5 |
Monthly Factsheet - July 2026
|
31 Aug 2026 3:47PM |
$50.310 |
$50.400 |
risen by
0.18%
|
|
| Synertec Corporation Limited (SOP) ORDINARY FULLY PAID |
Industrials |
$44 |
FY26 Financial Results & Key Achievements Investor Webinar
|
31 Aug 2026 3:46PM |
$0.055 |
$0.068 |
risen by
23.64%
|
|
| King River Resources Limited (KRR) ORDINARY FULLY PAID |
Materials |
$69 |
Application for quotation of securities - KRR
|
31 Aug 2026 3:46PM |
$0.078 |
$0.043 |
fallen by
44.87%
|
|
| Kalina Power Limited (KPO) ORDINARY FULLY PAID |
Utilities |
$36 |
Application for quotation of securities - KPO
|
31 Aug 2026 3:45PM |
$0.025 |
$0.012 |
fallen by
52%
|
|